Cipla reported a 39% decline in quarterly profit to ₹789 crore for Q1 FY27, largely due to lower sales of high-value products like lenalidomide compared to the previous year. While revenue increased slightly to ₹7,119 crore, investors are focusing on the company's US manufacturing footprint as a strategy to navigate potential trade tariffs.
Detailed Coverage
Cipla has reported its financial results for the first quarter ending June 30, 2026, showing a notable profit decline despite steady revenue growth. The pharmaceutical major recorded a Profit After Tax of ₹789 crore, down 39% from the ₹1,298 crore reported in the same period last year. Total revenue from operations reached ₹7,119 crore, a slight rise from ₹6,957 crore in the previous year's corresponding quarter.
Management attributed the drop in profit to a challenging comparison with the prior year, which benefited from higher sales of specific high-value products such as lenalidomide and lanreotide. As these products face market normalization, the company is now working to improve productivity and manage costs to stabilize profit margins.
Strategic Focus on US Manufacturing and Growth
To manage potential trade policy shifts, particularly the threat of increased US tariffs on generic drugs, Cipla is highlighting its production capabilities. Approximately 35% to 40% of the company's manufacturing capacity is already situated within the United States. This domestic presence is intended to provide a buffer against import-related disruptions. For the quarter, revenue from the North American market stood at $162 million, accounting for 22% of total sales.
In the domestic market, the company’s 'One India' business segment reached record sales of ₹3,452 crore, reflecting a 12% year-on-year growth. This segment remains the primary revenue driver, contributing 48% to the company's total sales. Cipla is also expanding its portfolio with the distribution of a second brand of the obesity medication Mounjaro in India. Management indicated that given the strong performance of this product, they may not prioritize alternative options like semaglutide for the local market.
Financial Position and Future Outlook
Cipla maintains a strong balance sheet with a cash reserve of ₹10,094 crore. This liquidity is earmarked for strategic expansion, specifically targeting complex products in the US market, growth in Europe, and the development of the biologics segment in India. However, not all segments performed well; the Active Pharmaceutical Ingredient (API) business saw a 28% decline in revenue to ₹160 crore, which the company linked to recent geopolitical conditions affecting supply chains.
Investors will likely monitor how effectively the company can scale its newer product launches to replace the revenue contribution of older, high-value drugs. Additionally, the ability of the US manufacturing operations to mitigate future tariff pressures and the recovery of the API business will be key factors for the company’s performance in the coming quarters.